{"id":35887,"date":"2019-03-28T09:46:26","date_gmt":"2019-03-28T09:46:26","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=35887"},"modified":"2019-07-23T23:38:14","modified_gmt":"2019-07-23T23:38:14","slug":"dolutegravir-3tc-dual-art-as-effective-at-lowest-viral-load-cut-off-as-triple-therapy-in-gemini-studies","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/35887","title":{"rendered":"Dolutegravir\/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies"},"content":{"rendered":"

\"\"Simon Collins, HIV i-Base<\/strong><\/p>\n

The phase 3 GEMINI 1 and 2 studies showed that dual therapy (2D) with dolutegravir\/3TC was non-inferior to triple therapy (3D) with dolutegravir plus TDF\/FTC, based on viral suppression at 48 weeks. <\/strong><\/p>\n

A new analysis, presented as a poster at CROI 2019, now also shows no differences between the two arms at viral load <40 copies\/mL.<\/p>\n

The analysis was based on participants with viral load <40 copies\/mL having either a target detected (TD) or target not detected (TND) result.<\/p>\n

At the primary 48 week endpoint and at all earlier time points there were no significant differences between the 2D vs 3D arms: 77% vs 73% (adjusted difference: 3.8%, 95% CI \u20130.6%, 8.2%).<\/p>\n

Proportions were similar at all other time points: 34% vs 32% (week 4), 52% vs 49% (week 8), 60% vs 57% (week 12), 59% vs 56% (week 16), 65% vs 63% (weeks 24) and 65% vs 68% (week 36), in the 2D vs 3D arms respectively.<\/p>\n

By baseline viral load, there was also no differences between arms in participants starting <100,000 copies\/mL but a numerical advantage for the 2D arm when baseline viral load was >100,000 copies\/mL (64% vs 52% (difference +12.7% (95%CI: 1.4 to 23.9). See Table 1.<\/p>\n

Time to TND was the same for both arms: 29 days\u00a0with baseline VL <100,000 and 57 days when >100,000 copies\/mL.<\/p>\n

\"\"<\/p>\n

Reference<\/p>\n

Underwood M et al.\u00a0HIV replication at <40 c\/mL for DTG+3TC vs DTG+TDF\/FTC in the GEMINI 1 & 2 studies. CROI, 4-7 March 2019, Poster abstract 490.
\nhttp:\/\/www.croiconference.org\/sessions\/hiv-replication<\/a>\u00a0(abstract)<\/p>\n","protected":false},"excerpt":{"rendered":"

Simon Collins, HIV i-Base The phase 3 GEMINI 1 and 2 studies showed that dual therapy (2D) with dolutegravir\/3TC was non-inferior to triple therapy (3D) with dolutegravir plus TDF\/FTC, based on viral suppression at 48 weeks. A new analysis, presented …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3,41],"tags":[264],"class_list":["post-35887","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","category-treatment-strategies","tag-croi-2019"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/35887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=35887"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/35887\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=35887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=35887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=35887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}